> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# PTC Therapeutics Authorizes Up To $500 Million Buyback, Calls Its Shares A 'Compelling Opportunity'
- URL: https://www.bullished.co/ptc-therapeutics-authorizes-up-to-500-million-buyback-calls-its-shares-a-compelling-46ade20f/
- Published: 2026-11-03T14:05:53.000Z
- Updated: 2026-11-03T14:05:53.000Z
- Description: The rare-disease drugmaker's board approved the repurchase program days after it raised its 2026 revenue guidance.
- Author: Matteo Parrino
- Tags: SEC Filings, PTCT, Industry: Healthcare

[PTC Therapeutics](https://www.bullished.co/tag/ptct/), a biopharmaceutical company that develops medicines for rare disorders, said Tuesday its board authorized the repurchase of [up to $500 million](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926121713/tmb-20261103x8k.htm?ref=bullished.co) of its common stock, subject to market conditions. The approval comes days after the company raised its full-year 2026 revenue guidance.

## How the buyback can be executed

Management decides when and how to buy. The company said purchases may come through open-market transactions, including pre-set trading plans, as well as privately negotiated deals, accelerated repurchases and other transactions that comply with securities law.

Results of any buying will show up in the company's quarterly 10-Q and annual 10-K reports, the [8-K](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926121713/tmb-20261103x8k.htm?ref=bullished.co) says.

## Klein's "compelling opportunity" pitch

CEO Matthew B. Klein said in the [company's announcement](https://www.prnewswire.com/news-releases/ptc-therapeutics-board-of-directors-authorizes-500-million-share-repurchase-program-302927094.html?ref=bullished.co) that the program reflects "deep conviction in the strength of the Company and the prospects for near- and long-term growth."

He added that PTC is investing in itself "at a time when our shares provide a compelling opportunity" while keeping the financial flexibility to support existing programs and pursue business development deals.

## Raised guidance, Sephience launch

The authorization follows PTC's [third-quarter report](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co), in which it lifted 2026 total revenue guidance to $1.29 billion to $1.32 billion, led by the Sephience launch. Sephience revenue was $182 million in the quarter, the company reported on October 29\. Klein said then that PTC was on track to reach cash flow breakeven this year.

Sephience treats phenylketonuria (PKU) and is approved in the United States, the European Economic Area and Japan, according to the company's annual report. PTC also sells Translarna and Emflaza for Duchenne muscular dystrophy, and receives Evrysdi revenue through its collaboration with Roche and the SMA Foundation. Its Huntington's disease drug votoplam is now led by Novartis.

PTC's shares trade on the Nasdaq Global Select Market under PTCT.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — PTC THERAPEUTICS, INC. (PTCT)](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926121713/tmb-20261103x8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tmb-ex99d1.htm — PTC THERAPEUTICS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926121713/tmb-ex99d1.htm?ref=bullished.co) — SEC EDGAR
- [PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program](https://www.prnewswire.com/news-releases/ptc-therapeutics-board-of-directors-authorizes-500-million-share-repurchase-program-302927094.html?ref=bullished.co) — prnewswire.com
- [PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co) — prnewswire.com

### More on PTC Therapeutics

- [PTC Therapeutics CEO Says Sephience Has Moved To 'Steady, Durable Growth' After Analyst Asks If Launch Is Slowing](https://www.bullished.co/ptc-therapeutics-ceo-says-sephience-has-moved-to-steady-durable-growth-after-analyst-asks-a069a277/)
- [PTC Therapeutics CEO Calls Sephience A 'Blockbuster' As Duchenne Drugs Lose Their Lift](https://www.bullished.co/ptc-therapeutics-ceo-calls-sephience-a-blockbuster-as-duchenne-drugs-lose-their-lift-1e28a2d5/)
- [PTC Therapeutics Paid $19.3 Million Over Face To Settle Its Last Old Convertible Notes](https://www.bullished.co/ptc-therapeutics-paid-19-3-million-over-face-to-settle-its-last-old-convertible-notes-2a1a26b8/)

[All PTC Therapeutics (PTCT) coverage →](https://www.bullished.co/tag/ptct/)